Cargando…

1529 Raltegravir Plus Tenofovir DF and Emtricitabine for Non-occupational Postexposure Prophylaxis (nPEP): African-Americans are at Higher Risk of Non-Completion of nPEP

Detalles Bibliográficos
Autores principales:	Vigil, Karen J., Simmons, Paul, Luna, Krystle, Martinez, Maria Laura, Hasbun, Rodrigo, Arduino, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781894/ http://dx.doi.org/10.1093/ofid/ofu052.1075

Ejemplares similares

992. Rethinking the 28-day HIV nPEP Dispensing Practice: A Pediatric ID Clinic Analysis
por: Zhang, David, et al.
Publicado: (2020)

Service acceptance of HIV non-occupational post-exposure prophylaxis(nPEP) among college students: a cross-sectional study in China
por: Liu, Tongtong, et al.
Publicado: (2021)

Improved awareness and appropriate use of non-occupational post-exposure prophylaxis (nPEP) for HIV prevention following a multi-modal communication strategy
por: Minas, Byron, et al.
Publicado: (2012)

Drug users’ awareness of and willingness to use HIV non-occupational post-exposure prophylaxis (nPEP) services in China: a mixed methods study
por: Jiao, Kedi, et al.
Publicado: (2022)

HIV non-occupational post-exposure prophylaxis (nPEP) awareness and promotion among five key populations in China: A cross-sectional study
por: Li, Haochu, et al.
Publicado: (2021)

Examining potential effects of non-occupational post-exposure prophylaxis (nPEP) on sexual behaviors of Chinese men who have sex with men: a cross-sectional study
por: Li, Haochu, et al.
Publicado: (2021)

1527 Longitudinal Trends in HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) at a Boston Community Health Center Between 1997 and 2013
por: Jain, Sachin, et al.
Publicado: (2014)

1567 Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF from ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF maintains HIV suppression and improves fasting triglycerides at week 48
por: Cunningham, Douglas, et al.
Publicado: (2014)

537 STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
por: Creticos, Catherine, et al.
Publicado: (2014)

936 Tolerability, Adherence and Completion of New Occupational HIV Post-Exposure Prophylaxis Regimens (Tenofovir + Emtricitabine and Raltegravir)
por: Bock, Izona, et al.
Publicado: (2014)

Development of the non-occupational post-exposure prophylaxis (NPEP) knowledge scale among Chinese men who have sex with men
por: Li, Haochu, et al.
Publicado: (2023)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

The PEP-N IP Magnet
por: Placidi, Massimo
Publicado: (2001)

The PEP-N interaction region
por: Sullivan, M, et al.
Publicado: (2001)

Pep for PEP-II
Publicado: (1995)

1591 Hepatitis B outcome in coinfected HIV-HBV individuals in the tenofovir/emtricitabine era
por: Nguyen, Divien, et al.
Publicado: (2014)

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2018)

Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF
por: Mills, Anthony, et al.
Publicado: (2015)

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF
por: Gathe, Joseph, et al.
Publicado: (2015)

1528 Ralteragir Containing regimen, for Post Exposure Prophylaxis (PEP), well tolerated in Health Care Workers (HCW)
por: Bourgi, Kassem, et al.
Publicado: (2014)

Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
por: Pohlman, F Will, et al.
Publicado: (2021)

Beams with PEP
Publicado: (1980)

PEP talk
Publicado: (1980)

PEP Workshop
Publicado: (1987)

Characterization of the Recombinant Exopeptidases PepX and PepN from Lactobacillus helveticus ATCC 12046 Important for Food Protein Hydrolysis
por: Stressler, Timo, et al.
Publicado: (2013)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-Naïve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine
por: Funderburg, Nicholas T., et al.
Publicado: (2013)

PEP Summer Study
Publicado: (1973)

PEP, and more besides...
Publicado: (1980)

Stanford: Lots of PEP
Publicado: (1978)

Feedback experiment at PEP
por: Donald, M, et al.
Publicado: (1986)

The PEP-II design
por: Sullivan, M K
Publicado: (1995)

PEP design handbook
por: Stanford Linear Accelerator Center. Stanford
Publicado: (1977)

PEP proposals, 1-
por: Stanford Linear Accelerator Center. Stanford
Publicado: (1976)

PEP Summer Study
por: University of California. Berkeley. Radiation Laboratory
Publicado: (1974)

PEP Summer Study
por: Stanford Linear Accelerator Center. Stanford, et al.
Publicado: (1973)

PEP Summer Study
por: University of California. Berkeley. Radiation Laboratory
Publicado: (1975)

The PETRA and PEP programmes
por: Wolf, G, et al.
Publicado: (1979)

Performance evaluation of PEP
por: Zisman, M S
Publicado: (1987)

Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s
por: Dirajlal-Fargo, Sahera, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rjck4s49rgs0uqkk72gj4ftlu6